Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 3, 2012, Pages 283-293

  Horsley, Laura ^a,b   Marti, Kalena ^a,b   Jayson, Gordon C ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Anti angiogenic drugs; Biomarkers; Hypertension; Outcome; Proteinuria; Toxicity

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB;

BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; NEOPLASMS; PATIENT SELECTION; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857291669     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.656845     Document Type: Review

References (78)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42 (Pubitemid 38702844)
3. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11 (Pubitemid 350296300)
4. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50 (Pubitemid 44917502)
6. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). June 20 2011: LBA5007
7. Kristensen G, Perren T, Qian W. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. ASCO Meeting Abstracts 2011;LBA5006
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
11. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
13. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24 (Pubitemid 46630489)
14. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329- 38 (Pubitemid 44528723)
15. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
16. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
17. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
18. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14(5):1407-12 (Pubitemid 351413922)
19. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16(4):558-65 (Pubitemid 40613321)
20. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743-8
21. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-77 (Pubitemid 46622044)
22. Baar J, Silverman P, Lyons J, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009;15(10):3583-90, CTCAE version 4;2010
23. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6 (Pubitemid 44325897)
24. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12 (Pubitemid 46630627)
25. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34 (Pubitemid 36910021)
26. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17(11):2793-800
27. van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997;95(4):1030-7 (Pubitemid 27091550)
28. Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010;56(6):1131-6
29. Ciuffetti G, Schillaci G, Innocente S, et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003;21(12):2297-303 (Pubitemid 38293569)
30. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19(5):927-34 (Pubitemid 351627309)
31. National Institute for Health and Clinical Excellence; Hypertension (CG127). London National Institute for Health and Clinical Excellence. 2011
32. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17(11):3841-9
33. George S, Lechner T, Li S, et al. Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU). ASCO Meeting Abstracts 2011;29(4 Suppl):38
34. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
35. Hurwitz H, Douglas PS, Middleton JP, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). ASCO Meeting Abstracts 2010;28(15 Suppl):3039
36. Kim RD, Byrne MT, Hammel J, et al. Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts 2010;28(15 Suppl):e14536
37. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the american heart association council on high blood pressure research. Circulation 2005;111(5):697-716 (Pubitemid 40216499)
38. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358(1):95-7
39. Tod M, Mir O, Bancelin N, et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011;28(12):3199-207
40. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15(19):6250-7
41. Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104(4):599-604
42. Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010;21(11):2220-6
43. Rugo HS, Herbst RS, Liu G, et al. Phase I Trial of the Oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
44. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50 (Pubitemid 32119100)
45. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186-93 (Pubitemid 46178407)
46. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23(5):460-8
47. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66(2):357-71
48. Kim JJ, Vaziri SAJ, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2011; (Published online 31/08/11)
49. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8
50. Newhouse SJ, Wallace C, Dobson R, et al. Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British genetics of hypertension study. Hum Mol Genet 2005;14(13):1805-14 (Pubitemid 41418052)
51. Frey MK, Olvera N, Bogomolniy F, et al. WNK1 haplotypes and bevacizumab-induced hypertension. ASCO Meeting Abstracts 2008;26(15 Suppl):11003
52. Jonasch E, Bair A, Chen Y, et al. Axitinib with or without dose titration as first-line therapy for metastatic renal cell Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers carcinoma (mRCC). ASCO Meeting Abstracts 2010;eTPS235
53. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
54. Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55:24-38
55. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111(5):707-16 (Pubitemid 36278589)
56. Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21(8):1381-9
57. Zee YK, Murukesh N, Kumaran G, et al. Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2010;e13580
58. Nangia CS, Wang D, Scarpace L, et al. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). ASCO Meeting Abstracts 2011;e2021
59. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer metastasis reviews 1990;9(3):267-82 (Pubitemid 20380383)
60. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90(12):1387-95 (Pubitemid 30032079)
61. Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29(22):2965-71
62. Hida T, Takeda K, Daga H, et al. A safety and tolerability study of vadimezan in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors. ASCO Meeting Abstracts 2010;e13106
63. Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22(9):2036-41
64. Rustin GJ, Shreeves G, Nathan PD, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010;102(9):1355-60
65. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
66. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71 (Pubitemid 350237599)
67. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6 (Pubitemid 350232248)
68. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20(2):227-30
69. De Stefano A, Cannella L, Carlomagno C, et al. Correlation between bevacizumab-related hypertension and response in mCRC patients. ASCO Meeting Abstracts 2010;28(15 Suppl):3581
70. Burnette BL, Grothey A. Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX. ASCO Meeting Abstracts 2010;28(15 Suppl):e14066
71. Radaideh SM, Gerber DE, Dunphy F, et al. Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. ASCO Meeting Abstracts 2010;28(15 Suppl):e18012
72. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28(6):949-54
73. Friberg G. Early hypertension (HTN) as a potential pharmacodynamic (PD) biomarker for survival in pancreatic cancer (PC) in patients treated with bevacizumab (B) and gemcitabine (G). ASCO Meeting Abstracts 2005;e3020
74. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20(2):393-4
75. Munoz J, Sanchez BE, Sharifi M, et al. Hypertension as a clinical marker of response to bevacizumab across malignancies. ASCO Meeting Abstracts 2011;29(15 Suppl):e16601
76. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18(6):1117 (Pubitemid 47050505)
77. Szmit S, Langiewicz P, Zlnierek J, et al. Hypertension as a Predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Pressure Res 2011;35(1):18-25
78. Rutkowski P, Bylina E, Switaj T, et al. An analysis of arterial hypertension and mutational status as predictive factors for results of sunitinib (SU) therapy in gastrointestinal stromal tumors (GIST). ASCO Meeting Abstracts 2011;29(15 Suppl):10017